Quick Answer
CytoDyn Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
CytoDyn Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.00 | +100.0% |
| 2024 | -$0.05 | +50.0% |
| 2023 | -$0.10 | +67.7% |
| 2022 | -$0.31 | -3.3% |
| 2021 | -$0.30 | +9.1% |
| 2020 | -$0.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | -$0.02 | — | — |
| August 31, 2025 | $0.00 | -100.0% | — |
| February 28, 2025 | $0.00 | +100.0% | — |
| November 30, 2024 | $0.00 | +100.0% | -100.0% |
| August 31, 2024 | $0.02 | +300.0% | +300.0% |
| February 29, 2024 | -$0.01 | +50.0% | +0.0% |
| November 30, 2023 | -$0.01 | +66.7% | +0.0% |
| August 31, 2023 | -$0.01 | +66.7% | +50.0% |
- CytoDyn Inc. showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, CytoDyn Inc.’s diluted eps has grown by 100.0% (from $0.33 per share (loss) to $0.00 per share).
- The most recent figure is from CytoDyn Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: